Risk Signals in Pharmaceutical Supply Chains: The Early Warning Gap
Executive summary
Pharmaceutical shortages are now treated by major regulators as a resilience problem rooted in quality failures, complex and concentrated supply chains, economic fragility in parts of the generic market, and weak cross-system coordination.
In the EU, EMA's European Shortages Monitoring Platform became mandatory on 2 February 2025 (EMA, 2025); the European Commission proposed the Critical Medicines Act on 11 March 2025 (European Commission, 2025a); the Council agreed its position on that proposal on 2 December 2025 (Council of the European Union, 2025a); and the Council and Parliament reached a provisional agreement on the broader pharma package on 11 December 2025, with formal adoption still required (Council of the European Union, 2025b).
In the U.S., GAO said in April 2025 that drug shortages remained a serious public-health problem, that shortages were lasting longer, and that shortages most commonly affected sterile injectables critical to hospital care and cancer treatment (GAO, 2025).
McKinsey's analysis of supply-chain disruption risk across industries estimates that companies can expect to lose, on average, more than 40 percent of one year's profits every decade to shocks lasting a month or longer (McKinsey Global Institute, 2020). For a mid-sized European pharmaceutical company generating €500 million in annual operating profit, that translates to roughly €200 million in avoidable losses per decade.
The defensible claim is not that all shortages are predictable. It is that a meaningful subset of supply disruptions are preceded by observable signals that can improve preparedness if monitored systematically. FDA itself states that local supply issues can signal a future shortage and that advance notice can help prevent or shorten a shortage (FDA, 2025a); GAO reported that FDA has been building data-analytic tools — including the Supply Chain Analytical Network System and the Insights Data Toolkit — to analyse supply-chain information and potentially predict disruptions (GAO, 2025); and FDA's FY2024 quality report describes integrated "product snapshots" that combine supply-chain data, complaints, recalls and distribution information to assess potential quality signals (FDA, 2025b).
1. Purpose, scope and evidence standard
This paper is written for VPs of supply chain, procurement leaders, board members, investment committees and regulatory affairs teams. It uses only official public sources from EMA, the European Commission, the Council of the European Union, FDA, HHS/ASPE and GAO. It separates enacted measures, legislative proposals and provisional political agreements.
It also avoids using a single headline percentage for Europe's external dependency on APIs, because official materials consistently identify serious vulnerabilities but the precise share varies by molecule, product class and definition.
In this paper, a risk signal means publicly observable information that materially changes the assessed probability or likely impact of a supply disruption. That is a narrower and more useful concept than "prediction." Good governance is not about claiming certainty; it is about improving lead time, prioritisation and response quality.
2. Current risk context
The regulatory direction is clear.
In the EU: EMA says the ESMP gives marketing authorisation holders and national competent authorities a single platform to report supply, demand and availability data, with harmonised reporting intended to improve the EU's ability to prevent and mitigate shortages (EMA, 2025). The Commission says the Critical Medicines Act was proposed to improve availability and supply, support manufacturing, and reduce vulnerabilities linked to single suppliers and third countries (European Commission, 2025a). The Council's December 2025 position added a resilience focus in procurement and facilitated collaborative procurement models (Council of the European Union, 2025a). On the broader pharma package, the Council said the provisional political agreement aims to strengthen security of supply to prevent and manage shortages, but also made clear that formal endorsement and adoption are still required (Council of the European Union, 2025b).
In the U.S.: FDA states that shortages can occur because of manufacturing and quality problems, delays and discontinuations, and that manufacturers should notify the agency about discontinuances, GMP issues, demand increases, recalls and supply interruptions (FDA, 2025a). GAO reported that as of 31 July 2024 FDA was tracking 102 drug shortages, that shortages were lasting longer, and that the most affected products continued to be sterile injectables important to hospital and cancer care. GAO also concluded that shortages are a multifaceted issue requiring more formal coordination across HHS (GAO, 2025).
3. Why early warning is plausible, but limited
The strongest case for early warning comes from official practice. FDA has already described analytical work intended to identify potential supply disruptions earlier, and it has shown how multi-source "product snapshots" can combine quality, recall, complaint and supply-chain data into a more actionable risk view (FDA, 2025b). The European Commission's 2022 supply-chain vulnerabilities paper likewise highlighted the need to unlock data for better supply and demand predictability and to understand where concentrated sources create the greatest risk in critical-medicine supply chains (European Commission, 2022).
That said, early warning has clear limits. Public data can lag internal manufacturing failures, some disruptions emerge too quickly for meaningful prevention, and no public signal set can guarantee a shortage will occur. The correct objective is therefore earlier and better action, not perfect forecasting.
The sartan contamination — a compact case study
In the sartan/nitrosamine episode, EMA required companies to review manufacturing processes to avoid nitrosamine impurities (EMA, 2018) and estimated that if 100,000 patients took affected Zhejiang Huahai valsartan every day for six years at the highest dose, there could have been 22 extra cancer cases over their lifetimes (EMA, 2020).
The lesson for governance is not that every contamination event can be predicted precisely. It is that upstream process change, constrained supplier optionality and weak visibility beyond the first tier can turn a local quality problem into a multi-country regulatory and supply event.
4. The five signal families that matter most
4.1 Regulatory and quality signals
Regulatory signals are the clearest public indicators of operational stress because they capture failures in process control, data integrity, contamination prevention and GMP compliance.
FDA reported 972 drug-quality inspections in FY2024, with more than 62% of inspections at foreign sites. The same report recorded 105 quality-related warning letters and 75 quality-related import-alert additions, and noted that warning letters to foreign sites increased while domestic warning letters decreased (FDA, 2025b).
For a board or diligence team, that means warning letters, import alerts, inspection outcomes, GMP non-compliance findings, contamination recalls and discontinuances linked to GMP issues should be treated as leading indicators of continuity risk, not as compliance issues to be handled in isolation.
4.2 Concentration and dependency signals
Concentration is the signal that amplifies every other signal. The European Commission's vulnerabilities paper identified increasing complexity, specialisation, lack of geographical diversification and concentrated sources as structural supply-chain weaknesses. It also stated that it would be useful to assess the extent to which companies rely on the same few raw-material or API sources and where the greatest risks sit in critical-medicine supply chains (European Commission, 2022).
The Commission's Critical Medicines Act materials define relevant vulnerabilities partly by reference to high dependencies on a single or limited number of third countries, while the Council's position stresses diversification and procurement resilience (Council of the European Union, 2025a).
In practice, the most useful metric is not a single Europe-wide dependency percentage, but molecule-level concentration by supplier, site, country and route.
4.3 Geopolitical and policy signals
Geopolitical and policy shifts matter because governments can alter supply availability or economics faster than most firms can qualify alternatives.
The Commission said in March 2025 that medicine shortages are mostly caused by manufacturing problems, supply-chain risks and global competition for resources (European Commission, 2025a). The Critical Medicines Act proposal and the Council's position both link resilience to diversification, collaborative procurement and stronger security-of-supply mechanisms. The provisional pharma package agreement likewise frames shortage prevention and security of supply as core policy objectives (Council of the European Union, 2025b).
For monitoring purposes, relevant signals include export controls, procurement rule changes, sanctions, customs frictions, industrial policy shifts and any regulatory move that increases resilience requirements for critical medicines.
4.4 Financial and market-structure signals
Financial fragility is a real risk signal even before formal quality action occurs. GAO said shortages arise partly because there are weak incentives to produce less profitable drugs and to invest in manufacturing quality. Its 2025 work also noted that sterile injectables — and generic versions in particular — are commonly in shortage because of manufacturing complexity combined with low prices and low profit margins (GAO, 2025).
HHS/ASPE found that from 2018 to 2023, 258 unique active ingredients entered national shortage, affecting 1,961 unique prescription products, and that generic shortage starts were more than twice as numerous as brand shortage starts (HHS/ASPE, 2025).
For boards and investors, that makes sustained margin compression, underinvestment, product rationalisation, ownership instability and exit risk material supply indicators rather than purely financial footnotes.
4.5 Environmental and logistics signals
Environmental and logistics shocks become shortage risks when manufacturing capacity or transport routes are concentrated. FDA said the 2017 Atlantic hurricanes shut down several important medical product manufacturing facilities in Puerto Rico, exacerbating shortages of IV saline and other fluids (FDA, 2018). FDA's shortages framework also explicitly treats supply interruptions, demand surges, recalls and GMP issues as reportable events with shortage implications (FDA, 2025a).
The practical implication is direct: weather exposure, power reliability, water availability, transport bottlenecks, route concentration and epidemic disruption should sit inside pharmaceutical risk monitoring, not outside it.
5. What procurement leaders, boards and investors should require
A credible early-warning capability should have four characteristics.
First, it should identify critical molecules, not just strategic suppliers. Criticality should reflect clinical importance, substitutability, revenue exposure and time-to-recover.
Second, it should map beyond tier 1 for the products that matter most. Full visibility across an entire portfolio may be unrealistic; partial visibility across the highest-risk molecules is not.
Third, it should use trigger-based escalation. A warning letter at a sole-source API site is not equivalent to the same warning letter at a diversified node. Response thresholds should vary with concentration, recoverability and patient impact.
Fourth, it should validate mitigations before a crisis. Dual sourcing, safety stock, dossier readiness, transport alternatives and customer communication plans are only useful when they are already operationally and regulatorily feasible.
For diligence purposes, management should be able to evidence five things on demand:
- a critical-molecule register
- tier-2 and tier-3 mapping coverage for the highest-risk products
- a documented signal taxonomy and monitoring cadence
- escalation thresholds linked to concentration and patient impact
- pre-validated mitigation options with realistic activation times
6. What this paper does not claim
This paper does not claim that every shortage is foreseeable or avoidable. It does not treat a proposal as though it were already enacted law. It does not assume that one headline dependency number can substitute for molecule-level exposure analysis. And it does not suggest that signal monitoring eliminates the need for inventory discipline, supplier qualification or regulatory readiness.
The claim is narrower and stronger: systematic monitoring of high-value public signals can materially improve preparedness, prioritisation and response quality.
Conclusion
Official EU and U.S. sources now converge on the same basic picture: pharmaceutical shortages are driven by a combination of quality failures, concentrated and complex supply chains, weak incentives in parts of the market, and incomplete coordination. Regulators are responding by building common monitoring tools, tightening resilience expectations and linking procurement more explicitly to security-of-supply objectives.
The operational conclusion is straightforward. Supply-chain risk management in pharmaceuticals is no longer credible if it stops at tier 1 or treats shortage prevention as a purely reactive function. The right standard for boards, investors and procurement leaders is not perfect prediction. It is disciplined visibility into the signals that precede disruption, clear governance over how those signals are assessed, and pre-validated actions that can be taken before patient access is compromised.
Published by Croft · Helsinki, Finland · April 2026
References
Council of the European Union (2025a) Critical medicines act: Council agrees its position on new rules to tackle shortages, 2 December. Available at: https://www.consilium.europa.eu/en/press/press-releases/2025/12/02/critical-medicines-act-council-agrees-its-position-on-new-rules-to-tackle-shortages/ (Accessed: 15 April 2026).
Council of the European Union (2025b) 'Pharma package': Council and Parliament reach a deal on new rules for a fairer and more competitive EU pharmaceutical sector, 11 December. Available at: https://www.consilium.europa.eu/en/press/press-releases/2025/12/11/pharma-package/ (Accessed: 15 April 2026).
European Commission (2022) Commission Staff Working Document on vulnerabilities of the global supply chains of medicines. Available at: https://health.ec.europa.eu/document/download/d6871c01-b30a-49d9-a780-6396e094e1f5_en (Accessed: 15 April 2026).
European Commission (2025a) Commission proposes new rules to ensure stable supply of critical medicines, 11 March. Available at: https://commission.europa.eu/news-and-media/news/commission-proposes-new-rules-ensure-stable-supply-critical-medicines-2025-03-11_en (Accessed: 15 April 2026).
European Commission (2025b) Critical Medicines Act: Factsheet — improving the availability and securing supply of critical medicines in the EU. Available at: https://commission.europa.eu/topics/public-health/european-health-union/modernising-eu-pharmaceutical-legislation_en (Accessed: 15 April 2026).
European Medicines Agency (2018) Sartan medicines: companies to review manufacturing processes to avoid presence of nitrosamine impurities, 21 November. Available at: https://www.ema.europa.eu/en/news/sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities (Accessed: 15 April 2026).
European Medicines Agency (2020) Lessons learnt from presence of N-nitrosamine impurities in sartan medicines: implementation plan. Available at: https://www.ema.europa.eu/en/documents/report/lessons-learnt-presence-n-nitrosamine-impurities-sartan-medicines_en.pdf (Accessed: 15 April 2026).
European Medicines Agency (2025) European Shortages Monitoring Platform fully operational for monitoring of shortages in the EU, 29 January. Available at: https://www.ema.europa.eu/en/news/european-shortages-monitoring-platform-fully-operational-monitoring-shortages-eu (Accessed: 15 April 2026).
McKinsey Global Institute (2020) Risk, resilience, and rebalancing in global value chains. Available at: https://www.mckinsey.com/~/media/mckinsey/business%20functions/operations/our%20insights/risk%20resilience%20and%20rebalancing%20in%20global%20value%20chains/risk-resilience-and-rebalancing-in-global-value-chains-full-report-vh.pdf (Accessed: 17 April 2026).
U.S. Department of Health and Human Services, ASPE (2025) Analysis of Drug Shortages, 2018–2023. Available at: https://aspe.hhs.gov/sites/default/files/documents/efa332939da2064fa2c132bb8e842bb5/Drug%20Shortages_Data%20Brief_Final_2025.01.10.pdf (Accessed: 15 April 2026).
U.S. Food and Drug Administration (2018) Report on Drug Shortages for Calendar Year 2017 (Required by Section 1002(c) of the Food and Drug Administration Reauthorization Act of 2017). Available at: https://www.fda.gov/files/drugs/published/Fifth-Annual-Report-on-Drug-Shortages-for-Calendar-Year-2017.pdf (Accessed: 17 April 2026).
U.S. Food and Drug Administration (2025a) Drug Shortages. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages (Accessed: 15 April 2026).
U.S. Food and Drug Administration (2025b) FY2024 Report on the State of Pharmaceutical Quality. Available at: https://www.fda.gov/drugs/pharmaceutical-quality-resources/fda-pharmaceutical-quality-oversight (Accessed: 15 April 2026).
U.S. Government Accountability Office (2025) Drug Shortages: HHS Should Implement a Mechanism to Coordinate Its Activities, GAO-25-107110. Available at: https://www.gao.gov/products/gao-25-107110 (Accessed: 15 April 2026).